Healthcare

Tyra Biosciences, Inc. (NASDAQ: TYRA) shares closed up 14% at $25.07 after the company announced the pricing of a $400 million underwritten public offering featuring common stock alongside pre-funded warrants at $22.03 per share equivalent, spearheaded by RACapitalalongside broad institutional backing.

Cellectis S.A. (NASDAQ: CLLS) shares closed down 41% at $1.83 after the company announced a strategic pivot toward in vivo gene-editing programs, focusing resources on .HEAL-101 for APOC3 in severe hypertriglyceridemia and .HEAL-201 for PCSK9 in severe hypercholesterolemia.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) was upgraded by B. Riley to Buy from Neutral, with the firm boosting its price target to $21 from $5.

Definium Therapeutics, Inc. (NASDAQ: DFTX) reported its second positive Phase 3 GAD study for DT120 ODT, with the Panorama trial meeting the Week 12 HAM-A primary endpoint at the 100 µg dose with a 5.1-point placebo-adjusted improvement and rapid onset by Day 2.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced the FDA granted Breakthrough Therapy designation to intravenous AP-SA02 as an adjunctive therapy for complicated Staphylococcus aureus bacteremia, covering both MSSA and MRSA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) shares closed up 47% at $2.44 after the company terminated its PC111 option and license agreement with PinCell following a denied extension request.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced favorable Phase 1b CANYON-1 trial results evaluating once-daily oral CRB-913 for obesity, demonstrating statistically significant weight reduction across all cohort dosages.